Lite Strategy (LITS) Other Non-Current Liabilities (2011 - 2025)
Lite Strategy (LITS) posted quarterly Other Non-Current Liabilities of $2.0 million for Q3 2025, down 59.18% year-over-year from $4.9 million in Q3 2024, and down 59.18% quarter-over-quarter from $4.9 million in Q1 2025.
Lite Strategy (LITS) Other Non-Current Liabilities (2011 - 2025) Analysis & Trends
Lite Strategy's Other Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $2.0 million for Q3 2025.
- In Q3 2025, Other Non-Current Liabilities fell 59.18% year-over-year to $2.0 million; the TTM figure through Sep 2025 stood at $2.0 million (down 59.18% YoY), while the FY2022 annual figure was $1.6 million, down 92.83% from the prior year.
- Other Non-Current Liabilities for Q3 2025 stood at $2.0 million, down from $4.9 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $29.4 million in Q1 2021, with the low at $500000.0 in Q3 2022.
- The 5-year median for Other Non-Current Liabilities is $4.9 million (2023), against an average of $8.7 million.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities slumped 97.47% in 2022, then soared 300.0% in 2023.
- Lite Strategy's Other Non-Current Liabilities stood at $14.3 million in 2021, then plunged by 96.51% to $500000.0 in 2022, then jumped by 880.0% to $4.9 million in 2023, then changed by 0.0% to $4.9 million in 2024, then sank by 59.18% to $2.0 million in 2025.
- Business Quant data shows LITS's Other Non-Current Liabilities at $2.0 million in Q3 2025, $4.9 million in Q1 2025, and $4.9 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 2.00 Mn |
| Mar 31, 2025 | 4.90 Mn |
| Dec 31, 2024 | 4.90 Mn |
| Sep 30, 2024 | 4.90 Mn |
| Dec 31, 2023 | 4.90 Mn |
| Sep 30, 2023 | 2.00 Mn |
| Sep 30, 2022 | 500,000.00 |
| Jun 30, 2022 | 1.60 Mn |
| Mar 31, 2022 | 1.54 Mn |
| Dec 31, 2021 | 14.31 Mn |
| Sep 30, 2021 | 19.77 Mn |
| Jun 30, 2021 | 22.36 Mn |
| Mar 31, 2021 | 29.44 Mn |
| Dec 31, 2020 | 20.18 Mn |
| Sep 30, 2020 | 27.26 Mn |
| Jun 30, 2020 | 40.50 Mn |
| Mar 31, 2020 | 16.78 Mn |
| Dec 31, 2019 | 16.78 Mn |
| Sep 30, 2019 | 8.34 Mn |
| Jun 30, 2019 | 17.61 Mn |